Eli Lilly may be on the brink of reshaping the pharma landscape, with its treatments, Mounjaro (tirzepatide) for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease.
Specific doses of Eli Lilly’s GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act – fast.
Eli Lilly is partnering with ecommerce titan Amazon to deliver its weight loss drug Zepbound straight to patient’s doors, in a bid to address ongoing shortages.
The unprecedented demand for GLP-1 medicines, fuelled by their remarkable ability to help patients shed up to 20% of body weight, has been nothing short of explosive.
Biogen’s stance at the upcoming AD/PD 2024 International Conference on Alzheimer’s disease and Parkinson’s disease will demonstrate its future plans for treating Alzheimer’s, following the discontinuation of Aduhelm (aducanumab), its anti-amyloid beta...
Novo Nordisk is set to acquire three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets.
Novo Nordisk's Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data, coupled with social media buzz and celebrity endorsements that elevated the drug to mainstream prominence.
Eli Lilly has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).
Eli Lilly’s blockbuster type 2 diabetes (T2B) drug Mounjaro is likely to become the dominant therapy in obesity and T2D, due to significant weight loss induced by it, says GlobalData.
The antibody drug donanemab, developed by the pharma giant Eli Lilly, has met all of its goals in a phase 3 trial for slowing cognitive decline in people with Alzheimer’s disease.
Following a recent phase 2 failure, the San Francisco-based biotech company Nektar Therapeutics has slashed its workforce and axed the development of the protein drug rezpegaldesleukin (Rezpeg) for the treatment of the autoimmune disease systemic lupus...
Eli Lilly and Company will make an equity investment of around $15m in MiNA Therapeutics: a company with a proprietary small activating RNA (saRNA) technology platform.
Eli Lilly and Company and MiNA Therapeutics Ltd have announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform.
Executives from the largest companies in the industry discuss the increasing prevalence of biologics and the future focus for therapeutics at Pharma Integrates.
As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.
Eli Lilly and Innovent announced that their jointly developed anti-PD-1 drug gained approval in China, becoming the second domestically produced treatment of this type.
Rumours of an Irish expansion freeze have been greatly exaggerated according to Eli Lilly, which says it remains committed to its Kinsale biomanufacturing site.
The thin profit margins associated with relatively simple sterile products has led to a reluctance to invest in operations and shortages, according to an industry expert.
Imclone has closed the manufacturing facility in Branchburg, New Jersey where it produces the cancer drug Erbitux, according to reports in the US media.
The FDA has issued Eli Lilly with a warning letter detailing a significant deviation from cGMP at its API production facility in Puerto Rico, which makes ingredients used in Humalog (insulin lispro), a diabetes treatment.
